Ratings Enhabit, Inc.

Equities

EHAB

US29332G1022

Real-time Estimate Cboe BZX 14:51:23 2024-06-26 EDT 5-day change 1st Jan Change
8.4 USD -0.12% Intraday chart for Enhabit, Inc. -4.77% -18.94%

Strengths

  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company is in debt and has limited leeway for investment
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.71 times its estimated earnings per share for the ongoing year.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-18.94% 422M -
-3.48% 3.01B
B-
+28.92% 1.95B
C
0.00% 1.83B -
+62.36% 678M
D+
-30.97% 149M -
-11.33% 136M -
+9.62% 66.59M - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes